



HCC- UK Annual Conference
'The MDT approach to HCC management'
Clare College, Cambridge

Thursday 21st March 2024 – Basic and Translational Science Day

11:00–12:00 Registration – arrivals, coffee and networking

Session 1 – Risk Prediction of liver disease and HCC (Chair: TBC)

12:00-12:05 Welcome and Introduction – Matt Hoare, University of Cambridge

12:05-12:30 Mendelian randomization: how can genetic variants help us triage therapeutic targets? - Stephen Burgess, Statistician, University of Cambridge

12:30-12:40 The impact of competing risk bias in prognostic models for hepatocellular carcinoma in patients with cirrhosis – Laura Burke, Leeds Teaching Hospitals Trust

12:40-13:05 Understanding risk for targeted surveillance strategies in HCC – Professor Pierre Nahon, Professor of Hepatology, APHP Avicenne Hospital

13:05-13:30 Genetic determinants of MASLD-HCC: from lipotoxicity to inflammation – Professor Luca Vittorio Carlo Valenti, Università degli Studi di Milano, Italy

13:30–14:40 Lunch and poster viewing

Session 2 – Molecular mechanisms and markers (Chair: Shish Shetty, Luca Valenti)

14:45 - 14:55 Unravelling bacterial metabolites using High-Resolution Magic-Angle-Spinning NMR spectroscopy in intact HCC liver tissue - Wendy Fernandes, Roger Williams Institute of Hepatology, Foundation for Liver Research.

14:55 - 15:05 The potential of BH3-mimetics as radio-sensitisation therapies in Hepatocellular carcinoma - Bashaer Alqarafi, CRUK Scotland Institute.

15:05 - 15:15 Exploring the role of TSPAN6 in regulating macrophage phenotype within the ductular reaction in the pre-cancerous niche - James Kennedy, University of Birmingham.

15:15 - 15:25 Investigation of Bap1 in hepatocarcinogenesis through the development of novel preclinical models of HCC - Anastasia Georgakopoulou, CRUK Scotland Institute.

15:25-15:35 Exploration of circulating blood cells RNA for predictive biomarker discovery in patients with hepatocellular carcinoma – Dr Ruchi Shukla, Northumbria University



15:35-16:00 Understanding the functional heterogeneity of hepatic macrophages in MASLD and MASLD-HCC – Professor Charlotte Scott, PI, VIB-UGent Center for Inflammation Research

16:00–16:40 Tea and Coffee

Session 3 – Tumour microenvironment and development (Chair: Tom Bird)

16:45 – 16:55 Immunosuppressive CD73 is upregulated on tumour endothelium and may limit effective immune infiltrate in hepatocellular carcinoma - Rosemary Faulkes, University of Birmingham.

16:55 - 17:05 Engineering NK cell immunotherapy to optimise liver homing and T cell regulation - Mariana Diniz, UCL.

17:05 – 17:15 CLEC14A regulates neutrophil recruitment across liver endothelial cells and correlates with a neutrophil signature in hepatocellular carcinoma - Shish Shetty, University of Birmingham.

17:15-17:45 Interplay between senescent cells and the adaptive immune system – Dr Manuel, Principal Investigator, Altos Labs, Cambridge Institute of Science

19:00 Dinner at Sidney Sussex College (arrival 7pm, dinner 7.30pm)

Friday 22nd March 2024 - Clinical Day

8:00-9:00 Registration and coffee

8:20-8:50 Symposium - AstraZeneca

9:00-9:05 Welcome and Introduction to the Clinical Day – Dr Teik See Choon and Dr Victoria Snowdon

Session 4 - Early detection and HCC prevention

9:05-10:25 Diagnostic difficulties in Hepatocellular carcinoma – Cases (25 mins each)

MDT panel: Dr Dave Bowden (radiology), Dr Teik See Choon (interventional radiology), Dr Owen Cain (pathology), Oncologist, Surgeon, CNS, Dr Louise Vine (hepatologist)

- Radiology perspective ‘atypical imaging features’ – Dr Dave Bowden, Consultant HPB/GI Radiologist, Cambridge University Hospitals
- Pathology perspective ‘well differentiated hepatocellular lesions’ – Dr Owen Cain, Consultant Histopathologist, Queen Elizabeth Hospital Birmingham



- Hepatology perspective 'detecting/ surveying small lesions / screening program' – Dr Louisa Vine, Consultant Hepatologist, Derriford Hospital

10:25-10:40 British Liver Trust – Liver cancer policy - Pamela Healy OBE, CEO, British Liver Trust

10:40-11:05 Improving health inequality in HCC diagnosis 'Community surveillance pilots' – Professor Graham Forster

11:05-12:00 Coffee, posters and exhibition

11:25-11:55 Symposium - Roche

Managing advanced HCC: Exploring patient journeys with systemic therapy

Dr Tony Dhillon - Consultant Medical Oncologist and Senior Lecturer in Oncology at the Royal Surrey Hospital NHS Foundation Trust and Dr Sanju Mathew - Consultant Gastroenterologist and Hepatologist at the Royal Surrey Hospital NHS Foundation Trust

Session 5 - Improving HCC outcomes

12:00-12:40 KEYNOTE Developments in the diagnosis and management of HCC – Professor John Olynyk, Associate Dean Medicine, Head of Medicine Discipline, Curtin University

12:30-12:50 HCC minimal listing criteria – Dr Abid Suddle

13:00-13:30 Expanding the utility of systemic therapy – neo adjuvant and adjuvant trials – Professor Tim Meyer, Experimental Cancer Medicine, UCL

13:30-14:35 Lunch, posters and exhibition

14:00-14:30 Symposium – Sirtex

HCC MDT – Interactive Cases

Professor Helen Reeves – Consultant Hepatologist – Newcastle

Professor Rohini Sharma – Consultant Medical Oncologist, Imperial College, London

Dr Teik Choon See - Consultant Interventional Radiologist, Cambridge University Hospitals NHS Foundation Trust

Session 6

14:35-15:15 Debate 'Resection versus RFA for smaller < 3cm tumours'

FOR: Professor Jens Ricke, Director Clinic and Polyclinic for Radiology, LMU Clinic Munich

AGAINST: Paul Gibbs

15:15-15:45 The evolving role of the HCC CNS - Sarah Selemeni, Leda Nurse – HCC, Kings College Hospital, London.

15:45-16:15 Intermediate stage HCC – what is best for my patient? TBC



16:15-16:45 Advanced stage HCC – what is best for my patient? (SS versus IR versus combination) –
Professor Ardnt Vogel, Physician scientist, Toronto General Hospital

16:45-16:50 Conclusion/Farewell

**This educational event is supported by an unrestricted grant from the following
commercial organisations:**

GOLD SPONSORS



SILVER SPONSORS



EXHIBITION SPONSORS

